The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.
https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png00https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png2024-09-20 17:08:512024-09-20 17:08:51F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.